- Home
- INO vs CGTX Comparison
INO vs CGTX Comparison
Compare INO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | CGTX |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.1M | 132.4M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INO | CGTX |
|---|---|---|
| Price | $1.58 | $1.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $9.00 | $3.33 |
| AVG Volume (30 Days) | ★ 1.1M | 970.8K |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $182,337.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23,060.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.22 |
| 52 Week High | $2.98 | $3.83 |
Technical Indicators
Market Signals| Indicator | INO | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 36.51 |
| Support Level | $1.54 | $0.98 |
| Resistance Level | $1.78 | $1.21 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 32.79 | 15.96 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.